Investor Presentaiton

Strong track record Unique model Large moat Significant opportunity Compounding growth Track record of delivering exceptional growth Adjusted Cash Receipts (1) Capital deployed (annual average) $1.05bn 2012 ~2x $2.13bn $1.49bn 2021 2012-2016 +41% ROYALTY PHARMA 1. Adjusted Cash Receipts for periods 2020 and earlier are pro forma for current non-controlling interests. See slide 114 for additional information. $2.10bn 2017-2021 11

View entire presentation